Berberine ameliorates testosterone-induced benign prostate hyperplasia in rats
© 2021. The Author(s)..
INTRODUCTION: Benign prostatic hyperplasia (BPH) is a major urologic problem that mostly develops in older males. Oxidative stress and inflammation influence the occurrence of BPH. Berberine (BBR) is a natural ingredient that has antioxidant and anti-inflammatory properties. The current research aims at examining the effects of BBR on testosterone-stimulated BPH in rats.
METHODS: Animals were randomly categorized to six groups. In the control group, normal saline and olive oil were injected as the vehicle. BPH group: received testosterone (3 mg/kg, subcutaneous, 28 days), BPH + BBR groups; received BBR (25 and 50 mg/kg, p.o, 28 days), BPH + finasteride groups: received finasteride (1 mg/kg, p.o, 28 days), BBR (50 mg/kg, p.o, alone) was administered for subjects in the BBR group. On the 29th day, after anesthesia, cervical dislocation was used to kill the subjects. Serum concentration of testosterone and dihydrotestosterone was measured and prostate tissues were excised and used for biochemical, inflammation, and histological analysis.
RESULTS: BBR prevented increased serum concentrations of testosterone and dihydrotestosterone. BBR considerably reduced BPH-stimulated oxidative stress and inflammation through preventing the rise in lipid peroxidation and nitrite concentration and declined the accumulations of pro-inflammatory cytokines (e.g. interleukin 1β and tumor necrosis factor α) and declining the depletion rate of GSH and the function of catalase and superoxide dismutase. Histopathological investigations reported that administration of BBR could suppress testosterone-stimulated BPH.
CONCLUSION: This study demonstrated that BBR could significantly prevent the development of BPH in rats.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
BMC complementary medicine and therapies - 21(2021), 1 vom: 20. Dez., Seite 301 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shabani, Ehsan [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 06.01.2022 Date Revised 04.04.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s12906-021-03472-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM334662648 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM334662648 | ||
| 003 | DE-627 | ||
| 005 | 20240404233717.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12906-021-03472-2 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1364.xml |
| 035 | |a (DE-627)NLM334662648 | ||
| 035 | |a (NLM)34930229 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shabani, Ehsan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Berberine ameliorates testosterone-induced benign prostate hyperplasia in rats |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.01.2022 | ||
| 500 | |a Date Revised 04.04.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021. The Author(s). | ||
| 520 | |a INTRODUCTION: Benign prostatic hyperplasia (BPH) is a major urologic problem that mostly develops in older males. Oxidative stress and inflammation influence the occurrence of BPH. Berberine (BBR) is a natural ingredient that has antioxidant and anti-inflammatory properties. The current research aims at examining the effects of BBR on testosterone-stimulated BPH in rats | ||
| 520 | |a METHODS: Animals were randomly categorized to six groups. In the control group, normal saline and olive oil were injected as the vehicle. BPH group: received testosterone (3 mg/kg, subcutaneous, 28 days), BPH + BBR groups; received BBR (25 and 50 mg/kg, p.o, 28 days), BPH + finasteride groups: received finasteride (1 mg/kg, p.o, 28 days), BBR (50 mg/kg, p.o, alone) was administered for subjects in the BBR group. On the 29th day, after anesthesia, cervical dislocation was used to kill the subjects. Serum concentration of testosterone and dihydrotestosterone was measured and prostate tissues were excised and used for biochemical, inflammation, and histological analysis | ||
| 520 | |a RESULTS: BBR prevented increased serum concentrations of testosterone and dihydrotestosterone. BBR considerably reduced BPH-stimulated oxidative stress and inflammation through preventing the rise in lipid peroxidation and nitrite concentration and declined the accumulations of pro-inflammatory cytokines (e.g. interleukin 1β and tumor necrosis factor α) and declining the depletion rate of GSH and the function of catalase and superoxide dismutase. Histopathological investigations reported that administration of BBR could suppress testosterone-stimulated BPH | ||
| 520 | |a CONCLUSION: This study demonstrated that BBR could significantly prevent the development of BPH in rats | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a BPH | |
| 650 | 4 | |a Berberine | |
| 650 | 4 | |a Inflammation, Rat | |
| 650 | 4 | |a Oxidative stress | |
| 650 | 4 | |a Testosterone | |
| 650 | 7 | |a Anti-Inflammatory Agents |2 NLM | |
| 650 | 7 | |a Antioxidants |2 NLM | |
| 650 | 7 | |a Drugs, Chinese Herbal |2 NLM | |
| 650 | 7 | |a Interleukin-1beta |2 NLM | |
| 650 | 7 | |a Tumor Necrosis Factor-alpha |2 NLM | |
| 650 | 7 | |a Dihydrotestosterone |2 NLM | |
| 650 | 7 | |a 08J2K08A3Y |2 NLM | |
| 650 | 7 | |a Berberine |2 NLM | |
| 650 | 7 | |a 0I8Y3P32UF |2 NLM | |
| 650 | 7 | |a Testosterone |2 NLM | |
| 650 | 7 | |a 3XMK78S47O |2 NLM | |
| 650 | 7 | |a Finasteride |2 NLM | |
| 650 | 7 | |a 57GNO57U7G |2 NLM | |
| 700 | 1 | |a Kalantari, Heibatullah |e verfasserin |4 aut | |
| 700 | 1 | |a Kalantar, Mojtaba |e verfasserin |4 aut | |
| 700 | 1 | |a Goudarzi, Mehdi |e verfasserin |4 aut | |
| 700 | 1 | |a Mansouri, Esrafil |e verfasserin |4 aut | |
| 700 | 1 | |a Kalantar, Hadi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMC complementary medicine and therapies |d 2020 |g 21(2021), 1 vom: 20. Dez., Seite 301 |w (DE-627)NLM306156547 |x 2662-7671 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2021 |g number:1 |g day:20 |g month:12 |g pages:301 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12906-021-03472-2 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2021 |e 1 |b 20 |c 12 |h 301 | ||